Aisling Capital Management as of March 31, 2025
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 13 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 72.7 | $210M | 6.1M | 34.57 | |
| Verona Pharma Sponsored Ads (VRNA) | 13.5 | $39M | 615k | 63.49 | |
| Syndax Pharmaceuticals (SNDX) | 4.4 | $13M | 1.0M | 12.28 | |
| Bicara Therapeutics (BCAX) | 2.6 | $7.4M | 569k | 13.03 | |
| Monte Rosa Therapeutics (GLUE) | 2.4 | $6.8M | 1.5M | 4.64 | |
| Nuvation Bio Com Cl A (NUVB) | 1.6 | $4.5M | 2.5M | 1.76 | |
| Compass Pathways Sponsored Ads (CMPS) | 1.2 | $3.4M | 1.2M | 2.86 | |
| Biomea Fusion (BMEA) | 0.6 | $1.7M | 799k | 2.13 | |
| CalciMedica Com New (CALC) | 0.3 | $995k | 521k | 1.91 | |
| Elevation Oncology (ELEV) | 0.3 | $735k | 2.8M | 0.26 | |
| Aclaris Therapeutics (ACRS) | 0.2 | $665k | 435k | 1.53 | |
| Marker Therapeutics Com New (MRKR) | 0.1 | $400k | 325k | 1.23 | |
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $381k | 89k | 4.30 |
